Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
73,010 results
  • Antithrombotic treatment after stroke due to intracerebral haemorrhage. [Review]
    Cochrane Database Syst Rev. 2023 Jan 26; 1:CD012144.Cochrane A, Chen C, … Al-Shahi Salman R
  • CONCLUSIONS: We did not identify beneficial or hazardous effects of short-term prophylactic dose parenteral anticoagulation and long-term oral antiplatelet therapy after ICH on important outcomes. Although there was a significant reduction in MACE and all major occlusive vascular events after long-term treatment with therapeutic dose oral anticoagulation for atrial fibrillation after ICH, the pooled estimates were imprecise, the certainty of evidence was only moderate, and effects on other important outcomes were uncertain. Large RCTs with a low risk of bias are required to resolve the ongoing dilemmas about antithrombotic treatment after ICH.
  • Thromboprophylaxis in Patients With Fontan Circulation. [Journal Article]
    J Am Coll Cardiol. 2023 Jan 31; 81(4):374-389.Van den Eynde J, Possner M, … Alsaied T
  • CONCLUSIONS: Aspirin, warfarin, and NOAC are associated with lower risk of thromboembolic events. Recognizing the limited number of patients and heterogeneity of studies using NOACs, the results support the safety and efficacy of NOACs in patients with a Fontan circulation.
  • Intravenous immunoglobulin for the treatment of Kawasaki disease. [Review]
    Cochrane Database Syst Rev. 2023 Jan 25; 1:CD014884.Broderick C, Kobayashi S, … Kobayashi T
  • CONCLUSIONS: The included RCTs investigated a variety of comparisons, and the small number of events observed during the study periods limited detection of effects. The certainty of the evidence ranged from moderate to very low due to concerns related to risk of bias, imprecision, and inconsistency. The available evidence indicated that high-dose IVIG regimens are probably associated with a reduced risk of CAA formation compared to ASA or medium- or low-dose IVIG regimens. There were no clinically significant differences in incidence of adverse effects, which suggests there is little concern about the safety of IVIG. Compared to ASA, high-dose IVIG probably reduced the duration of fever, but there was little or no difference detected in the need for additional treatment. Compared to medium- or low-dose IVIG, there may be reduced duration of fever and reduced need for additional treatment. We were unable to draw any conclusions regarding acute coronary syndromes, mortality, or length of hospital stay, or for the comparison IVIG versus prednisolone. Our findings are in keeping with current guideline recommendations and evidence from long-term epidemiology studies.
  • Health-related heterogeneity in brain aging and associations with longitudinal change in cognitive function. [Journal Article]
    Front Aging Neurosci. 2022; 14:1063721.Wrigglesworth J, Ryan J, … Harding IH
  • CONCLUSIONS: These results demonstrate that the relationship between brain age and cognitive trajectories may be influenced by other health-related factors. In particular, people with age-resilient brains had different trajectories of cognitive change depending on their cognitive and physical health status at baseline. Future predictive models of aging outcomes will likely be aided by considering the mediating or synergistic influence of multiple lifestyle and health indices alongside brain age.
New Search Next